Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Duchenne Development: Six-Minute Walk Losing Favor?

Executive Summary

Sarepta relied on the endpoint to get accelerated approval for eteplirsen, but the interim CEO says trials for follow-on products could use walk-run tests or other measures instead.

Advertisement

Related Content

Exondys Approval: Measured Efficacy Outcomes Vs. Patient 'Anecdotes'
Keeping Track: Ilaris Adds Three Rare Disease Claims; Sirukumab Submitted; Exondys 51's Surprising Approval
Eteplirsen Review Offers Lessons For FDA, Advocacy Groups, Industry
Accelerated Approval After Eteplirsen: A Lowered Bar Or A Unique Event?
Accelerated Approval After Eteplirsen: A Lowered Bar Or A Unique Event?
Sarepta, FDA And The Dangers Of Strong Early Results
FDA Can’t Find Efficacy For BioMarin’s Drisapersen
Duchenne Muscular Dystrophy: FDA Supports Broader Outcome Measures, Biomarkers

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119167

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel